1 rich Libsyn https://www.libsyn.com 90 600 The recent expansion of the topical ruxolitinib approval to include pediatric patients aged 2 to 11 years with atopic dermatitis (AD) provides the first JAK inhibitor therapy option for this young population. In this episode, &quot;Management of Atopic Dermatitis with JAK Inhibitors: A Pediatric to Geriatric Perspective,&quot; expert dermatologists, Christopher Bunick, MD, PhD and Karan Lal, DO discuss: Importance of JAK/STAT signaling in AD and the role of JAK inhibition in the future of dermatology Long-term safety of topical therapies for chronic AD Topline efficacy safety data from the phase 3 TRuE-AD3 clinical trial Shifting the paradigm of topical AD care across patient populations DermDocs http://dermdocs.libsyn.com/website <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/38373800/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/193510635